<DOC>
	<DOCNO>NCT01158885</DOCNO>
	<brief_summary>This study test ability clofarabine + cytarabine eliminate minimal residual disease ( MRD ) acute myelogenous leukemia ( AML ) acute lymphoblastic leukemia ( ALL ) patient whose bone marrows exhibit complete remission morphology . The toxicity profile regimen evaluate addition toxicity experience patient proceed stem cell transplant . Overall length remission also collect .</brief_summary>
	<brief_title>Clofarabine With Cytarabine Patients With Minimal Residual Disease Positive Leukemia</brief_title>
	<detailed_description>Recent study demonstrate even low level minimum residual disease ( MRD ) ( &gt; 0.01 % abnormal blast ) aggressive re-induction therapy indicate relatively poor outcome relapse acute lymphoblastic leukemia ( ALL ) patient , include proceed allogeneic stem cell transplant ( alloSCT ) . A similarly poor prognosis see pediatric acute myelogenous leukemia patient sub-morphologic disease prior alloSCT . Studies identify therapy eliminate persistent leukemia , low toxicity profile serve bridge transplant need . This study test ability clofarabine + cytarabine eliminate minimal residual disease ( MRD ) acute myelogenous leukemia acute lymphoblastic leukemia patient whose bone marrows exhibit complete remission morphology . The toxicity profile regimen evaluate addition toxicity experience patient proceed stem cell transplant . Overall length remission also collect .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Neoplasm , Residual</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Clofarabine</mesh_term>
	<criteria>Patients must meet follow criterion eligible participate study . Patients must ≥1 ≤ 21 year age enrol onto study . Diagnosis ( Patient must follow ) Patients must diagnosis relapsed acute myelogenous leukemia ( AML ) acute lymphoblastic leukemia ( ALL ) Patient must M1 marrow base upon recovered marrow le 5 % blast conventional morphology Patient must minimal residual disease ( MRD ) detect either multidimensional conventional flow cytometry great 0.1 % le 5 % follow reinduction attempt Patients must central nervous system ( CNS ) disease status 1 Patient must absolute neutrophil count ( ANC ) &gt; 500/μL cytokine support least 24 hour platelet &gt; 50,000 K/μL without platelet transfusion past seven day Karnofsky &gt; 50 % patient &gt; 10 year age Lansky &gt; 50 % patient ≤ 10 year age . Patient must adequate venous access . Patients must fully recover acute toxic effect prior chemotherapy , immunotherapy , radiotherapy prior enter study . At least 21 day must elapse prior chemotherapy , least 7 day must elapse since receive biological therapy . It must least 90 day higher dose cytarabine therapy ( &gt; 1 gm/ m2/day ) . Patients must normal calculated creatinine clearance Patient must 1 . Conjugated ( direct ) serum bilirubin ≤ 1.5 x upper limit normal ( ULN ) age . 2 . Alanine transaminase ( ALT ) ≤ 2.5 × ULN age . 3 . Alkaline phosphatase ≤ 2.5 × ULN age . 4 . Serum amylase ≤ 1.5 ULN age . 5 . Serum Lipase ≤ ULN age . Patient must shorten fraction &gt; 28 % ejection fraction &gt; 50 % . Female patient childbearing potential must negative urine serum pregnancy test confirm prior enrollment . Female patient infant must agree breastfeed infant study . Male female patient childbearing potential must agree use effective method contraception approve investigator study . Patient must agree submission blood bone marrow assessment minimal residual disease ( MRD ) . All patient and/or parent legal guardian must sign write informed consent . Patients meet follow criterion exclude participate study . Patients previous hematopoietic stem cell transplant ( HSCT ) within previous six month . Patients prior treatment clofarabine . Patients CNS2 CNS 3 disease bulky chloromatous disease . Patients Down Syndrome . Patients previous history venoocclusive disease ( VOD ) finding consistent diagnosis VOD . Patients systemic fungal , bacterial , viral , infection control . Use investigational agent within 30 day plan treatment protocol . Patient receive plan receive concomitant chemotherapy , radiation therapy , immunotherapy anticancer therapy specify protocol . Pregnant lactating patient . Any significant concurrent disease , illness , psychiatric disorder social issue would compromise patient safety compliance , interfere consent , study participation , follow , interpretation study result . Have diagnosis another malignancy , unless patient diseasefree least 3 year follow completion curative intent therapy follow exception : 1 . Patients treat nonmelanoma skin cancer , situ carcinoma , cervical intraepithelial neoplasia , regardless diseasefree duration , eligible study definitive treatment condition complete . 2 . Patients organconfined prostate cancer evidence recurrent progressive disease base prostatespecific antigen ( PSA ) value also eligible study hormonal therapy initiate radical prostatectomy perform .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>relapse</keyword>
	<keyword>relapse</keyword>
	<keyword>refractory</keyword>
	<keyword>Minimal Residual disease</keyword>
	<keyword>MRD</keyword>
	<keyword>MRD positive</keyword>
	<keyword>MRD+</keyword>
	<keyword>ALL</keyword>
	<keyword>Acute lymphoblastic leukemia</keyword>
	<keyword>AML</keyword>
	<keyword>Acute myelogenous leukemia</keyword>
	<keyword>Relapsed AML</keyword>
</DOC>